EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2051-1426

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer ; volume:1 ; number:1 ; day:7 ; month:11 ; year:2013 ; pages:1 ; date:11.2013
Journal for ImmunoTherapy of Cancer ; 1, Heft 1 (7.11.2013), 1, 11.2013

Creator: Sasada, Tetsuro

Contributor: Yamada, Teppei
Azuma, Koichi
Matsueda, Satoko
Itoh, Kyogo
SpringerLink (Online service)

DOI: 10.1186/2051-1426-1-S1-P235

URN: urn:nbn:de:1111-2016072652875

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:56 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Sasada, Tetsuro
Yamada, Teppei
Azuma, Koichi
Matsueda, Satoko
Itoh, Kyogo
SpringerLink (Online service)

Other Objects (12)

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study

Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study

Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study

Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study

Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study

Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study

Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study

Related objects

Reset password